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Mortality in Fibromyalgia: A Study of 8,186
Patients Over Thirty-Five Years
FREDERICK WOLFE,1 AFTON L. HASSETT,2 BRIAN WALITT,3 AND KALEB MICHAUD4
Objective. To determine if mortality is increased among patients diagnosed as having fibromyalgia.
Methods. We studied 8,186 fibromyalgia patients seen between 1974 and 2009 in 3 settings: all fibromyalgia patients in
a clinical practice, patients participating in the US National Data Bank for Rheumatic Diseases (NDB), and patients
invited to participate in the NDB who refused participation. Internal controls included 10,087 patients with osteoarthritis.
Deaths were determined by multiple source communication, and all patients were also screened in the US National Death
Index (NDI). We calculated standardized mortality ratios (SMRs) based on age- and sex-stratified US population data,
after adjustment for NDI nonresponse.
Results. There were 539 deaths, and the overall SMR was 0.90 (95% confidence interval [95% CI] 0.61–1.26). Among 1,665
clinic patients, the SMR was 0.92 (95% CI 0.81–1.05). Sensitivity analyses varying the rate of NDI nonidentification did
not alter the nonassociation. Adjusted for age and sex, the hazard ratio for fibromyalgia compared with osteoarthritis was
1.05 (95% CI 0.94–1.17). The standardized mortality odds ratio (OR) compared with the US general population was
increased for suicide (OR 3.31, 95% CI 2.15–5.11) and for accidental deaths (OR 1.45, 95% CI 1.02– 2.06), but not for
malignancy.
Conclusion. Mortality does not appear to be increased in patients diagnosed with fibromyalgia, but the risk of death from
suicide and accidents was increased.
INTRODUCTION
Fibromyalgia arose as a common clinical diagnosis around
1980 (1–3), and the American College of Rheumatology
(ACR) provided classification criteria for the disorder in
1990 (4). Most evidence suggests that fibromyalgia is not a
discrete medical disorder, but rather that it represents the
end of a continuum of polysymptomatic distress (5,6),
though some would demur (7). The ACR 1990 criteria
required that chronic widespread pain be present for a
fibromyalgia diagnosis, and widespread pain, therefore,
lies on the pathway to fibromyalgia. One population-based
epidemiologic study found that chronic widespread pain
was associated with the risk of increased mortality (8),
although that finding has not been confirmed in another
large population-based study (9). Chronic severe pain, in-
cluding pain caused by cancer and angina, has been shown
to be associated with increased mortality (10).
There are several reasons why mortality might be in-
creased in fibromyalgia. Patients with the disorder are
substantial users of analgesics and antidepressants (11),
have many somatic symptom disorders (12), and have high
rates of depression (13,14). It seems possible that depres-
sion, sociodemographic characteristics, or iatrogenesis
could lead to increased mortality. The risk could also be
increased if fibromyalgia is a representation of more exten-
sive widespread pain or more severe symptoms.
We hypothesized that fibromyalgia not associated with
another important illness (“primary” fibromyalgia) will
have no association or only a slight association with mor-
tality and that fibromyalgia that occurs in the presence of
another important illness (secondary or concomitant fibro-
myalgia) will have such an association. The latter type of
fibromyalgia has been confirmed by increased rates of fi-
bromyalgia occurring in patients with other medical dis-
orders (15).
The current study of 8,186 fibromyalgia patients with
primary fibromyalgia attempts to answer the question of
whether primary fibromyalgia is associated with an in-
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creased risk of mortality. The best answer to such a ques-
tion should come from population-based data. Although
there have been population surveys to determine fibromy-
algia prevalence using the ACR 1990 criteria, the number
of cases identified are too few to determine subsequent
mortality risk, with the result that there are no population-
based mortality studies of fibromyalgia. An earlier clinical
study from Denmark did not find mortality increased in
fibromyalgia (16).
In the current report, we use clinical patients to make
inferences about mortality using standardized mortality
ratios (SMRs). This can be an uncertain process if clinic
patients differ systematically from persons in the general
population, differences that could occur if the studied
fibromyalgia patients have more or less severe fibromyal-
gia or have different sociodemographic characteristics
than persons in the general population. To help interpret
fibromyalgia data, we used 10,087 internal osteoarthritis
(OA) controls to determine if the risk of mortality differs
between the groups. We used OA patients because their
risk of mortality is close to that of the general population,
or only slightly increased (17), and because they have pain
problems as well. Patients with OA have been used as
controls for fibromyalgia criteria studies (4,18).
MATERIALS AND METHODS
Three related data sets (sources) were used in this study.
Of the 8,186 patients with fibromyalgia, 1,115 came from
the community clinical practice of the senior author (FW)
and were not enrolled in the National Data Bank for Rheu-
matic Diseases (NDB) longitudinal study of rheumatic dis-
ease outcomes. This group was called the Wichita nonpar-
ticipant group. There were 3,589 patients referred to the
NDB by US rheumatologists who elected not to participate
in the NDB (NDB nonparticipants), and 3,482 who became
participants in the NDB. Participation required the com-
pletion of detailed semiannual questionnaires. The rea-
sons for nonparticipation are not known; nonparticipation
is discussed further in the Discussion section. Of the NDB
participants, 550 came from the senior author’s practice
(FW) and represented all fibromyalgia patients seen in his
clinic during the years 1974 to 2004. They were diagnosed
using criteria in effect at the time of entry (4,19,20). Of the
1,115 patients seen by the senior author, 476 were first
seen prior to 1990, the year of the publication of the ACR
1990 classification criteria (4). The NDB was established
and began enrolling patients in 1998. Diagnoses for non-
Wichita patients were made by referring rheumatologists.
We also analyzed data from the 3 sources for patients with
OA. We used these patients to provide internal controls for
mortality analyses. Of the 10,087 OA patients, 4,073 were
NDB non-enrollees, 4,550 were NDB enrollees, and 1,464
were Wichita non-NDB enrollees. All Wichita OA patients
had OA of the knee or hip. Of the NDB OA patients, 3,402
had OA of the knee or hip; the remainder carried a diag-
nosis of OA without further specification. The overall
mean  SD age of the OA patients was 64.6  12.2 years,
and 77.9% were women.
The NDB obtains participants primarily by rheumatolo-
gist referral, and in these cases the rheumatologist pro-
vides the diagnosis. A small minority of participants enroll
from other sources, including self-referral, after obtaining
information from physicians, societies, and web sites. In
such cases the NDB obtains diagnostic confirmation from
the participants’ physicians. There were 19 Canadian pa-
tients with fibromyalgia in the NDB. These patients were
not included in the study because we used only US death
source information.
Study variables. The NDB surveys patients by detailed,
28-page postal or internet questionnaires at 6-month inter-
vals (21). Although not used for entry criteria for patients
in this study, 4 study variables were related to diagnostic
classification for NDB patients and were used in the ana-
lysis of NDB data: the fibromyalgianess scale (22,23), the
Widespread Pain Index (WPI) (18,24), widespread pain
(from the ACR 1990 criteria definition) (4), and fibromyal-
gia diagnosis modified (23) from the ACR 2010 diagnostic
criteria (18). To be clear, the modified diagnostic criteria
and the fibromyalgianess scale are not part of the ACR
2010 criteria, although the modifications to the 2010 cri-
teria that allow survey research were made by ACR 2010
criteria authors. The WPI is a count of the number of 19
nonarticular regions noted to be painful. In the NDB sur-
veys these data are obtained by self-report. The presence of
widespread pain is determined from the examination of
specific painful regions, and widespread pain is said to be
positive if there is pain above and below the waist, on the
left and right side of the body, and in the axial skeletal
region (4). Patients are considered to be fibromyalgia cri-
teria–positive if they satisfy modified ACR 2010 prelimi-
nary diagnostic criteria. In a previous study, we modified
these criteria so that they could be used for survey research
(23). However, some of the 2010 criteria variables were not
available prior to 2009. Therefore, we used the symptom
intensity scale (SI) (25) to derive diagnostic criteria and
fibromyalgianess scales in this study. The fibromyalgian-
ess scale is similar to the previously described SI scale
(24). Although the SI scale combines a visual analog scale
(VAS) fatigue scale with the WPI, and the fibromyalgianess
scale combines the WPI with a 4-item symptom severity
scale (not available in this study), the 2 scales are effec-
tively the same in terms of performance. When the SI scale
is transformed to the same scale length of the fibromyal-
gianess scale (0–31), the Pearson’s correlation coefficient
of the scales is 0.963 and Lin’s concordance coefficient is
0.956 (18). This indicates that the scales have almost the
exact same performance characteristics, i.e., “The scale
captures well the essential content of fibromyalgia or what
we have called ‘fibromyalgianess’” (22). The modification
of the 2010 criteria for diagnosis with data prior to 2009 in
the NDB was: (WPI 7 and VAS fatigue 5) or ([WPI 7
and VAS fatigue 5] and a count of somatic symptoms
13).
Additional clinical variables included the Health As-
sessment Questionnaire (HAQ) (26), the physical and men-
tal component summary scores from the Short Form 36
health survey (27,28), and VAS scales for pain, fatigue, and
patient global severity.
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Although we collected data on disease duration, there is
no agreed upon definition of disease duration in fibromy-
algia, and we do not know how individual study physi-
cians or patients defined onset. It is possible that the
disorder might be defined by the onset of many somatic
symptoms or the first regional or local pain problem, rather
than the onset of generalized pain or fibromyalgia diagno-
sis. We present duration data in relation to suicide data
because it may offer some explanatory information, but we
urge extreme caution in relying on or extrapolating from
these data (caveat lector).
Death data. The NDB obtains death information, in-
cluding cause of death, from families and physicians. Fol-
lowup for mortality began at entry into the cohort. In
addition, all patients, whether they are known to be alive
or not, are submitted annually to the US National Death
Index (NDI), since the NDI provides cause of death infor-
mation (29,30). The NDI receives all reports of deaths from
the individual states, and represents the repository of all
individual death information in the US. The NDI reports
lag behind actual deaths. To account for this, we censored
patients whose death status was not known as of December
31, 2007. The sensitivity of the NDI death ascertainment
depends upon the availability of the social security num-
ber (SSN) identifier (31). The NDI identified 97% of deaths
over a 6-year period when the SSN was available and 87%
when not available in one study, and this proportion fell to
85% in women without SSNs (32). The SSN and non-SSN
rates were 92% and 87%, respectively, in another study of
men (33). For privacy reasons, full SSNs were not available
to the NDB. The last 4 digits of the SSN were collected in
recent years in the NDB; overall, 25.2% of fibromyalgia
patients in this study had last 4-digit SSN data available.
Statistical analysis. Because the literature cited in the
paragraph above suggested underestimation of deaths de-
rived from the NDI for NDB participants and NDB nonpar-
ticipants, we used the information from the paragraph
above and our experience with NDB data to estimate an
under-identification rate of 12%. We then used a random
number generator to randomly change 12% of patients
classified as being alive to being dead to account for this
potential misclassification. We did not increase the num-
ber of deaths for the Wichita patients because internal
studies of Wichita mortality over a 20-year period indi-
cated 100% death capture. We used the determined deaths
plus the randomly added deaths as the observed deaths in
this report. In the analyses described below, we performed
sensitivity analyses by increasing randomly created deaths
to 20% and then measured the effect on SMRs. To deter-
mine SMRs from survival analyses, we used the Stata
strate (Stata) procedure and age-, sex-, and calendar-strat-
ified reference mortality rates from the US white general
population (34,35). SMRs that included multiple groups
used jackknife confidence intervals clustered on the
groups. Cause-specific mortality data were obtained from
National Vital Statistics Reports for 2006 (36). We calcu-
lated the standardized mortality odds ratio (OR) based on
the age- and sex-stratified number of deaths from underly-
ing specific causes in the general population and in study
subjects (without the random 12% increase in deaths).
Comparison of the risk of mortality for fibromyalgia
versus OA utilized Cox regression clustered, where appro-
priate, on source groups. Predictors of mortality were an-
alyzed using Cox regression adjusted for age and sex. All
analyses were performed using Stata, version 11.0 (Stata)
(34). Statistical significance was set at 0.05, and all tests
were 2-tailed.
RESULTS
There were 8,186 patients with fibromyalgia distributed
across the 3 source groups (Table 1), including a total of
1,665 from the Wichita clinical practice. The mean  SD
time in the study, from entry to death or censoring, was
7.3  5.9 years (range 0.1–31 years) or through 60,413
patient-years of followup. NDB fibromyalgia patients had
high levels of pain (6.4), fatigue (7.0), and global severity
(5.5) at entry. Widespread pain was identified in 81.4% of
Table 1. Characteristics of NDB participants with
fibromyalgia*
Variable Mean  SD
Age, years†
NDB non-enrollees (n  3,589,
93.1% women)
50.4  12.6
NDB enrollees (n  3,482, 95.4%
women)
51.7  11.9
Wichita non-NDB (n  1,115,
91.3% women)
47.0  12.9
All sources (n  8,186, 93.9%
women)
50.5  12.4
High school graduate, % 93.7
College graduate, % 29.5
Non-Hispanic white, % 92.8






Body mass index, kg/m2 30.1  7.6
HAQ score (0–3) 1.1  0.6
Pain score (0–10) 6.4  2.3
Global severity score (0–10) 5.5  2.4




Mental component summary score 41.6  12.2
Fibromyalgia diagnosis by modified
ACR 2010 criteria, %
67.4
Widespread pain, % 81.4
NDB fibromyalgianess scale (0–31) 19.1  7.3
* Medical insurance, marital status, smoking status, body mass
index, HAQ score, pain, physical and mental component summary
scores, modified ACR criteria diagnosis, and fibromyalgia diagnosis
were only available in NDB participants. Other demographics are
available in the NDB nonparticipant and the Wichita cohorts.
NDB  National Data Bank for Rheumatic Diseases; HAQ  Health
Assessment Questionnaire; ACR  American College of Rheuma-
tology.
† Represents age at study start.
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patients; 67.6% of patients satisfied modified survey diag-
nostic criteria.
Risk of mortality by source group. Fibromyalgia
patients differed as to their risk of mortality according
to the source group. After adjustment for age and sex, the
risk of mortality for NDB non-enrollees was hazard ratio
(HR) 1.56 (95% confidence interval [95% CI] 1.27–2.91)
and HR 1.77 (95% CI 1.42–2.19) for Wichita non-NDB
patients compared with NDB enrollees.
SMR. Source group differences translated into differ-
ences in the SMR when fibromyalgia patients were com-
pared with the US population, stratified by age and sex
(Table 2). Wichita non-NDB patients had the largest SMR
at 1.11 (95% CI 0.95–1.29), and NDB patients had the
smallest SMR at 0.67 (95% CI 0.58–0.78). When the
groups were combined, the overall SMR was 0.90 (95% CI
0.61–1.26). When NDB patients who satisfied the survey
modification of the ACR 2010 criteria were studied, their
SMR was 0.85 (95% CI 0.72–1.02). We also determined the
SMR of all Wichita patients regardless of whether they
were NDB participants or not. For this group the SMR was
0.92 (95% CI 0.81–1.05).
In a sensitivity analysis, we assumed that the NDI under-
identification of deaths was 20%, instead of the 12% as-
sumption used for all other analyses, and we randomly
increased the observed deaths by 20%. We then analyzed
the 3 source groups and found that the overall SMR was
0.96 (95% CI 0.65–1.38). Therefore, the result of all of the
study analyses under 2 assumptions suggests no increase
in mortality in patients with fibromyalgia.
Comparison with OA patients. We also used internal
controls to assess the risk of mortality in fibromyalgia by
comparing fibromyalgia patients with those with OA in
Cox regression analyses adjusted for age and sex. As
shown in Table 3, there was no increased risk associated
with fibromyalgia overall (HR 1.05, 95% CI 0.94–1.17), nor
when the analyses were restricted to OA patients with
known OA of the hip or knee.
Cause-specific mortality. Table 4 shows major causes of
death in the study patients compared with the US popu-
lation, after stratification for age and sex. The standardized
mortality OR was increased for suicide (OR 3.31, 95% CI
2.15–5.11), accidental deaths (OR 1.45, 95% CI 1.02–2.06),
septicemia (OR 2.49, 95% CI 1.61–3.68), and influenza and
pneumonia (OR 1.69, 95% CI 1.12–2.57), but not for ma-
lignancy (OR 0.95, 95% CI 0.76–1.18). Figure 1 shows that
death from suicide occurs soon after entry into the study in
contradistinction to other death causes. The mean  SD
age of the 15 fibromyalgia patients who died from suicide
was 46.5  11.4 years at entry into the study compared
with 60.2  13.0 years for those who died of other causes,
and their disease duration was 16.4 years (n  11) com-
pared with mean  SD 12.5  12.1 years for those who
died of other causes.
Predictors of mortality in the NDB fibromyalgia popu-
lation. Table 5 displays a series of Cox regression analyses
in which each analysis was adjusted for age and sex.
Fibromyalgianess and satisfying the survey-modified ACR
2010 criteria at entry, but not widespread pain, was asso-
ciated with an increased risk of mortality. Education level
and sex were not associated with risk of mortality, but all
other demographic and clinical variables contributed to
the risk.
DISCUSSION
The results of this study suggest that mortality is not
increased in fibromyalgia. Within the NDB participant
Table 2. SMR for fibromyalgia and fibromyalgia groups*
Group Patients, no. Deaths Expected deaths SMR 95% CI
NDB non-enrollees 3,589 186 173.52 1.07 0.92–1.24
NDB enrollees 3,482 187 277.79 0.67 0.58–0.78
Wichita non-NDB 1,115 166 149.40 1.11 0.95–1.29
All patients† 8,186 539 600.71 0.90 0.61–1.26
Wichita NDB enrollees and non-enrollees 1,665 221 239.56 0.92 0.81–1.05
NDB enrollees, ACR 2010 criteria positive 2,265 122 142.77 0.85 0.72–1.02
* SMR  standardized mortality ratio; 95% CI  95% confidence interval; NDB  National Data Bank for Rheumatic Diseases; ACR  American
College of Rheumatology.
† Clustered on fibromyalgia groups.
Table 3. Risk of mortality in fibromyalgia compared
with OA*
Source HR P > z 95% CI
All OA group
All† 1.05 0.410 0.94–1.17
NDB non-enrollees 1.15 0.162 0.94–1.40
NDB enrollees 0.98 0.788 0.82–1.17
Wichita non-enrollees 1.04 0.665 0.86–1.27
Known OA of hip/knee
All†
NDB non-enrollees 1.03 0.788 0.78–1.38
NDB enrollees 0.90 0.298 0.73–1.10
Wichita non-enrollees 1.04 0.665 0.86–1.27
* Adjusted for age and sex. OA  osteoarthritis; HR  hazard ratio;
95% CI  95% confidence interval; NDB  National Data Bank of
Rheumatic Diseases.
† Clustered on fibromyalgia groups.
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group, however, fibromyalgia patients satisfying modified
ACR 2010 criteria at entry had an increased risk of death
(HR 1.62, 95% CI 1.19–2.21). Recent studies have shown
that at least 25% of patients carrying a diagnosis of fibro-
myalgia do not satisfy ACR 1990 or 2010 criteria, or sur-
vey-modified 2010 criteria (4,18,23). In fact, 32.6% of pa-
tients in the NDB participant group did not meet the
survey-modified 2010 criteria. This occurs primarily be-
cause patients improve and/or symptoms lessen. So when
fibromyalgia is being considered with respect to mortality
in this study, we are de facto including all patients who
have been diagnosed with fibromyalgia and are generally
considered to be “fibromyalgia patients.”
The risk of mortality was increased in NDB non-enroll-
ees (HR 1.56, 95% CI 1.27–2.91), and Wichita non-enroll-
ees (HR 1.77, 95% CI 1.42–2.19) compared with NDB
enrollees. A wide variety of studies have shown lower
mortality rates in voluntary participants than nonpartici-
pants (37–39). As an example, “Out of 10,000 men invited
to a screening examination . . . in Goteborg, Sweden, 25%
did not come to the examination,” “The annual mortality
among the nonparticipants was about twice that of the
participants during the entire follow-up period of 11.8
years” (40). In the current study, mortality was less in NDB
participants compared with NDB nonparticipants, and
was consistent with the studies cited above (37–40). The
Wichita nonparticipant group can be considered equiva-
lent to a mixture of nonparticipants and participants, since
85% of this group of clinic patients were evaluated before
the existence of the NDB and could not have been NDB
participants. To account for the differences among the 3
groups, we calculated the overall SMR, after clustering on
group. The combined SMR was 0.90 (95% CI 0.61–1.26).
Although the NDB enrollees reduced the overall SMR,
none of the groups had a significant mortality increase. We
further studied mortality in the Wichita clinic patients by
including the Wichita nonparticipants with Wichita pa-
tients who became part of the NDB. The SMR for this
combined group was 0.92 (95% CI 0.81–1.05).
There is also support for the finding of no increase in
mortality by comparing fibromyalgia mortality with OA
mortality. In all Wichita patients, the HR for mortality,
adjusted for age and sex, was 1.13 (95% CI 0.96–1.33), and
in all patients in the study the HR was 1.02 (95% CI
0.97–1.07). There is some controversy as to whether mor-
tality is increased in OA. In a review, Hochberg concludes,
“Overall, there was moderate evidence of increased mor-
tality among persons with osteoarthritis compared with
the general population” (17). However, as Hochberg points
out, this conclusion is dependent on how OA is defined. In
a study by Watson and colleagues that used the UK Gen-
eral Practice Research Database in 61,517 men and 101,757
women with a clinical diagnosis of OA, the rates of age-
adjusted all-cause mortality per 1,000 patient-years were
19.5 and 15.9 in men and women with OA, respectively,
and 20.6 and 17.3 in men and women with no arthritis,
respectively (41). The authors concluded that the rates in
patients with OA and those with no arthritis were essen-
tially the same. The major limitation of this study was that
the diagnosis of OA was recorded by general practitioners
using unknown criteria. It seems possible that the mortal-
Table 4. Percent of deaths by leading causes for all fibromyalgia patients*
Cause of death Patients, % US population, % SMR (95% CI)
Heart diseases 22.9 26.0 0.84 (0.68–1.04)
Malignant neoplasms 22.2 23.1 0.95 (0.76–1.18)
Accidents (unintentional injuries) 7.1 5.0 1.45 (1.02–2.06)
Chronic lower respiratory diseases 5.6 5.1 1.09 (0.74–1.62)
Influenza and pneumonia 5.0 2.3 1.69 (1.12–2.57)
Septicemia 4.5 1.4 2.49 (1.61–3.68)
Intentional self-harm (suicide) 4.4 1.4 3.31 (2.15–5.11)
Cerebrovascular diseases 4.2 5.7 0.75 (0.48–1.17)
Nephritis/nephrotic syndrome/nephrosis 2.2 1.9 0.93 (0.50–1.72)
Alzheimer’s disease 1.7 3.0 0.57 (0.29–1.13)
Essential hypertension/hypertensive renal disease 1.1 1.0 0.95 (0.40–2.23)
Chronic liver disease and cirrhosis 0.7 1.1 0.47 (0.16–1.38)
Parkinson’s disease 0.2 0.8 0.22 (0.00–1.23)
Assault (homicide) 0.3 0.8 0.26 (0.00–1.51)
* Includes National Data Bank of Rheumatic Diseases participants and nonparticipants and Wichita nonparticipants. SMR  standardized mortality
ratio; 95% CI  95% confidence interval.
Figure 1. Kaplan-Meier survival estimates comparing death by
suicide with all other causes of death in patients with fibromyal-
gia.
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ity rate might have been increased had validated criteria
been used.
In determining SMRs, we ran into the problem of under-
estimating mortality in determining deaths using the NDI.
For reasons of privacy and patient acceptability, the NDB
did not have full SSNs. However, 25% of patients pro-
vided the last 4 digits of the SSN, and this enabled us to
match to full SSNs in the NDI in this group of patients. As
indicated in the Materials and Methods section (31–33),
the sensitivity of the NDI for identification of deaths is
85% for women in the absence of SSNs. To compensate
for this deficiency, we randomly increased the number of
deaths by 12% among NDB enrollees and NDB nonpartic-
ipants. We did not increase the deaths for Wichita non-
enrollees because internal studies indicated 100% death
capture among the Wichita patients. Since the interpreta-
tion of the SMR depends on the level of additional deaths
added in the NDB section of the study, we performed a
sensitivity analysis in which we increased deaths by 20%.
In this analysis we did not see an overall increase in SMR
compared with the US general population. Although these
data have a degree of uncertainty, we found no evidence to
suggest an increase in mortality among fibromyalgia pa-
tients.
There are few data regarding mortality in fibromyalgia.
Mäkelä and Heliövaara reported no increase in mortality
in a Finnish population study (42). However, they used an
ad hoc definition of fibromyalgia that is inconsistent with
all criteria definitions. Dreyer et al reported, in an abstract/
presentation in 2004, on 1,217 confirmed cases of fibromy-
algia in Danish women seen between 1984 and 1999 (16).
The SMR was not increased and there was no increase in
mortality from cancer. In a 2010 update of that study (43),
the authors confirmed the cancer findings and noted addi-
tionally an increased risk of suicide in fibromyalgia.
Andersson studied 214 persons with widespread (n 
70) or local (neck-shoulder) pain or without chronic pain
recruited from the general population and reported in-
creased mortality in those with widespread pain after 12
years followup (44). Macfarlane and colleagues found an
increase in mortality in a population study of persons with
widespread pain in the UK (8), and this increase has been
attributed to an increase in cancer cases (45,46). However,
a subsequent study has not confirmed the association of
widespread pain and mortality (9).
In agreement with the Danish report and in contradis-
tinction to the reports of the increase in cancer in patients
with widespread pain (45,46), we did not find increased
cancer mortality among fibromyalgia deaths (Table 4), and
we did find increases in suicide and accidental deaths.
Further, almost 20% of deaths attributed to accidents may
actually be suicides (47), so the OR that we found for
suicide of 3.31 (95% CI 2.15–5.11) might be closer to 4.0 if
accidents were misattributed. We also found an increase in
deaths from pneumonia/influenza and septicemia, a result
for which we have no medical explanation, and a result
that should be accepted with caution and will require
confirmation.
There is no clear-cut interpretation of the finding that
death from suicide is an early phenomenon (Figure 1). One
possibility is that the severity of symptoms led to physi-
cian visits and consequent study entry, and the severity
subsequently lessened. This would suggest an association
of health-seeking behavior and psychological problems,
such as depression, in some patients with fibromyalgia.
The relationship between suicide and antidepressant ther-
apy is tenuous (48), and we did not have sufficient data to
evaluate that possibility. Our data concerning suicide
should not be interpreted to suggest that fibromyalgia
symptoms cause suicide, since our data are cross-sectional
and associative, not causative.
The association of fibromyalgia diagnosis based on the
Table 5. Predictors of mortality in National Data Bank of Rheumatic Diseases enrollees with fibromyalgia*
HR SE z P 95% CI
Fibromyalgianess 1.05 0.01 4.21 0.000 1.02–1.07
Fibromyalgia criteria (positive) 1.62 0.26 3.03 0.002 1.19–2.21
Widespread pain (positive) 1.28 0.23 1.35 0.178 0.90–1.82
Age, years 1.05 0.01 8.88 0.000 1.05–1.07
Sex, male 1.01 0.33 0.04 0.967 0.53–1.92
High school graduate 0.82 0.20 0.82 0.412 0.51–1.31
College graduate 1.02 0.18 0.12 0.908 0.72–1.44
Married vs. divorced/separated 0.73 0.11 2.00 0.045 0.54–0.99
Married vs. all 0.63 0.15 1.99 0.047 0.39–0.99
Body mass index 29 kg/m2 1.54 0.23 2.83 0.005 1.14–2.07
HAQ (0–3) 1.99 0.24 5.79 0.000 1.58–2.52
Fatigue (0–10) 1.09 0.03 2.81 0.005 1.03–1.16
Pain (0–10) 1.17 0.05 3.59 0.000 1.08–1.28
Mood (0–10) 1.07 0.05 1.62 0.105 0.99–1.16
Physical component score 0.95 0.01 5.26 0.000 0.93–0.97
Mental component score 0.99 0.01 1.94 0.052 0.98–1.00
Smoking vs. never
Past 1.42 0.24 2.10 0.036 1.02–1.96
Current 2.63 0.55 4.61 0.000 1.74–3.97
* Each line represents a separate analysis that was adjusted for age at study entry and sex, except for age and sex, each of which were adjusted for each
other. HR  hazard ratio; 95% CI  95% confidence interval; HAQ  Health Assessment Questionnaire.
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2010 ACR criteria and on fibromyalgianess suggests that
the extent of widespread pain (beyond satisfying the wide-
spread pain criterion) and its accompanying severity may
be the prime determinant of increased mortality within the
widespread pain group. NDB participants satisfying the
modified 2010 criteria had an increased SMR (0.85) com-
pared with the overall NDB participant SMR (0.67).
Practically speaking, fibromyalgia has been a clinical
diagnosis rather than a disorder that can be studied in the
general population. This occurs because the prevalence of
fibromyalgia is low and its identification requires a phys-
ical examination, according to ACR 1990 criteria. It may
well be that the actual SMR would have been greater had
patients identified in population surveys been studied. But
there are no such patients. The patients in our study may
have had better socioeconomic status, since almost all
(94%) had medical insurance and all received care from
specialists rather than general physicians, which may be a
measure of social class and access to care. Factors such as
these have been shown to be associated with increased
survival (49,50).
In summary, the overall SMR in patients with fibromy-
algia was 0.90 (95% CI 0.61–1.26). Among 1,665 clinic
patients the SMR was 0.92 (95% CI 0.81–1.05). Sensitivity
analyses varying the rate of NDI nonidentification did not
alter the nonassociation. Adjusted for age and sex, the HR
for fibromyalgia compared with OA was 1.05 (95% CI
0.94–1.17). However, the standardized mortality OR was
increased for suicide (OR 3.31, 95% CI 2.15–5.11) and for
accidental deaths (OR 1.45, 95% CI 1.02–2.06), but not for
malignancy.
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